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ABSTRACT 
Metastatic uveal melanoma (UM) is invariably fatal, usually within a year of diagnosis. There 
are currently no effective therapies, and clinical studies employing kinase inhibitors have so 
far demonstrated limited success. This is despite common activating mutations in GNAQ/11 
genes, which trigger signalling pathways that might predispose tumours to a variety of 
targeted drugs. In this study, we have profiled kinome expression network dynamics in 
various human ocular melanomas. We uncovered a shared transcriptional profile in human 
primary UM samples and across a variety of experimental cell-based models. The poor 
overall response of UM cells to FDA-approved kinase inhibitors contrasted with much higher 
sensitivity to the bromodomain inhibitor JQ1, a broad transcriptional repressor. 
Mechanistically, we identified a repressed FOXM1-dependent kinase sub-network in JQ1-
exposed cells that contained multiple cell cycle-regulated protein kinases. Consistently, we 
demonstrated vulnerability of UM cells to inhibitors of mitotic protein kinases within this 
network, including the investigational PLK1 inhibitor BI6727. We conclude that analysis of 
kinome-wide signalling network dynamics has the potential to reveal actionable drug targets 
and inhibitors of potential therapeutic benefit for UM patients. 
SIGNIFICANCE 
Therapeutic options for metastatic uveal melanoma (UM) are inadequate, despite molecular 
lesions in kinase-based signalling networks. Unbiased transcriptional analysis of the entire 
UM kinome reveals a simple signature that is common to all experimental models and 
clinical samples. We find that a significant proportion of the UM kinome is transcriptionally 
down-regulated after exposure to the cytotoxic BET-domain inhibitor JQ1, including a 
FOXM1-regulated network of mitotic protein kinases. Consistently, targeting of this hub with 
kinase inhibitors, exemplified by the phase III investigational PLK1 inhibitor BI6727, induces 
a more selective profile of UM cytotoxicity. Future studies might evaluate the potential 
therapeutic value of anti-mitotic agents such as BI6727 in metastatic UM. 
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INTRODUCTION 
Uveal melanoma (UM) is the most common primary intraocular malignancy in adults, and 
arises from neoplastic melanocytes within the middle (vascular) layer in the eye. It is a rare 
tumour, with an incidence of 5-8 per million individuals per year amongst Caucasian 
populations (Damato, Eleuteri, Taktak, & Coupland, 2011). Despite successful treatment of 
the primary tumour by either surgery and/or radiotherapy (Damato, 2012), UM has an 
enigmatic propensity for metastasis to the liver in up to 50% of patients, and once this 
occurs, the two year life expectancy is currently only ~8% (Amaro et al., 2017; Carvajal et 
al., 2017; Diener-West et al., 2005). UM is characterised by activating mutations in D 
subunits of GNAQ or GNA11 genes in approximately 85% of cases (Van Raamsdonk et al., 
2009; Van Raamsdonk et al., 2010), and a lack of BRAF, PI3K or NRAS mutations 
(Griewank et al., 2012). In contrast, BRAF and NRAS mutations are common in cutaneous 
melanomas (Thomas, Edmiston, Alexander, & et al., 2015), where GNAQ/11 mutations are 
very rare (Yilmaz et al., 2015).  Even less common than UM is its extraocular counterpart 
conjunctival melanoma (CoM), which occurs in the outer mucous membranes of the eye in 
0.2-0.8 per million individuals per year (Kalirai & Coupland). It is also markedly different to 
UM genetically, being characterised by activating BRAF mutations in ~35% of cases (Larsen 
et al., 2016), and an absence of GNAQ or GNA11 mutations.  
Metastatic CoM containing BRAF mutations has been treated with some success with BRAF 
kinase inhibitors (Kao, Afshar, Bloomer, & Damato, 2016), although primary or secondary 
resistance is inevitable, and very few other treatment options are available. In metastatic 
UM, progress has been slower still (Carvajal et al., 2017), with kinase inhibitors showing very 
limited clinical efficacy, and no clear improvement in overall survival in phase II trials of the 
multi-kinase inhibitor sunitinib or the MEK inhibitor selumetinib (Blum, Yang, Komatsubara, & 
Carvajal, 2016; Carvajal et al., 2014). The therapeutic potential of modulating signalling 
pathways that lie downstream of constitutively active GNAQ/11, such as AKT, PKC, mTOR 
and the Hippo-YAP pathway is currently being evaluated (Carita et al., 2016; Feng et al., 
2014; Shoushtari & Carvajal, 2016; Yu et al., 2014). In addition, targeting cell cycle-regulated 
protein kinases remains an attractive approach for therapy in a wide range of solid tumours 
(Otto & Sicinski, 2017), although, to our knowledge, this avenue has not been explored 
experimentally for metastatic UM. 
A complementary (or alternative) therapeutic strategy in UM involves the repression of pro-
proliferative transcriptional networks driving growth and survival in tumour cells. 
Mechanistically, this involves drug-mediated disruption of the interaction between 
bromodomain-containing proteins, such as BRD4, and acetylated lysine residues on 
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chromatin-bound histones. Bromodomain Extra Terminal inhibitors (BETi), such as the MYC-
gene targeting compound JQ1, compete for the acetyl-binding pocket of transcription factors 
such as BRD4, and block: a) transcription of genes associated with G1/M progression (Dey, 
Nishiyama, Karpova, McNally, & Ozato, 2009); b) the recruitment of P-TEFb (Bisgrove, 
Mahmoudi, Henklein, & Verdin, 2007); c) the expression of the master oncogene MYC 
(Delmore et al., 2011); and d) activity of the BRD family themselves (Filippakopoulos et al., 
2010). JQ1 is a potent cellular BETi with high selectivity for BET domains of BRD-related 
transcription factors, particularly bromodomains 1 and 2 of BRD4 (Kd values ~50 nM and 
~90 nM respectively). Subsequently, the cytotoxic effects of JQ1 have been reported in a 
wide number of solid (Bandopadhayay et al., 2014; Cheng et al., 2013; Delmore et al., 2011) 
and haematological malignancies (Mertz et al., 2011; Ott et al., 2012). JQ1 exhibits 
extensive repressive effects on proliferative gene expression, and anti-cancer effects are 
thought to be achieved, in large part, by silencing MYC-dependent genes, such as the AP-1 
transcription factor FOSL1 (Baker et al., 2015), and the pro-proliferative Forkhead family 
member FOXM1 (Z. Zhang et al., 2016). In both GNAQ/11-mutant UM cell lines and a 
xenografted murine model, JQ1 arrests cell cycle progression in G1 phase in vitro, whilst 
apoptosis in UM is associated with the repression of Rad51 and Bcl-xL-dependent signalling 
pathways (Ambrosini, Sawle, Musi, & Schwartz, 2015).  More recently, dual kinase-
bromodomain inhibitors exemplified by the Polo-like kinase (PLK) inhibitors BI-2536 (Scutt et 
al., 2009; Steegmaier et al., 2007) and BI6727 (Rudolph et al., 2009) have been reported, 
raising the possibility that these rationally-designed dual inhibitors might have widespread 
therapeutic potential (Ciceri et al., 2014). 
In this paper, we employ kinome-wide transcriptomics to discover a new mRNA expression 
signature that is shared between human pigmented uveal and conjunctival melanomas, 
irrespective of GNAQ/11 or BRAF mutational status and chromosome 3 copy number. This 
kinome ‘fingerprint’, comprising very low levels of EGFR and high levels of CDK2 mRNAs, is 
also present in archived patient UM samples and in public data available from the The 
Cancer Genome Atlas (TCGA) database, where four molecular and clinical UM sub-classes 
have recently been recognized (Robertson et al., 2017). We also demonstrate that the 
cytotoxic BETi JQ1 strongly represses a FOXM1-dependent kinase transcriptional network 
containing cell cycle-related protein kinases in UM cells. Consistently, UM cell lines exposed 
to investigational anti-mitotic kinase inhibitors were cytotoxic, and selective UM susceptibility 
to the phase III PLK1 inhibitor BI6727/volasertib was observed.  We conclude that kinome-
wide analysis of transcription has the potential to expose vulnerabilities in signalling 
networks for evaluation as novel therapeutic targets in UM patients. 
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RESULTS 
Discovery of a kinome signature in UM and CoM cells 
Given the overall low mutational burden in UM, epigenetic mechanisms have recently been 
proposed to shape the gene transcription networks that regulate UM metastasis (Decatur et 
al., 2016; Royer-Bertrand et al., 2016). To help understand steady-state and dynamic 
programmes of transcription in human UM kinomes, we explored mRNA levels in patient 
samples deposited in TCGA. Principal component analysis (PCA) (Ringner, 2008) was 
employed to compare variance in whole kinome expression from 80 UM patient samples 
against a broad panel of distinct tumour samples, including cutaneous melanomas, an 
ER+/HER2 subset of breast cancer, cervical and colon cancer samples (Figure 1A).  This 
analysis revealed unique clustered kinome expression in all UM samples, which was distinct 
from other types of tumour sample examined. Interestingly, although UM were most similar 
to cutaneous melanomas, a clear distinction in kinome profile was still evident between 
these two tumour types. 
Human UM cell lines have been widely employed to compare transcription (An et al., 2011), 
signalling and drug responses in vitro and ex vivo. Sequencing of UM cell lines demonstrate 
common patterns of distinct genomic mutations in GNAQ/11 and BAP-1 genes, similar to 
tumour samples from patients (Supplementary Table 1). These profiles are proving useful as 
both diagnostic and prognostic markers (Staby et al., 2017). We profiled four well-studied 
UM cell lines, including 92.1 (derived from a primary UM), which responds to the BETi JQ1 
in vivo when implanted in a rodent tumour model (Ambrosini et al., 2015), Mel270 (derived 
from a primary UM), OMM2.5 (a liver metastasis from the same patient as Mel270) and 
OMM1, a subcutaneous metastasis. In addition, the CoM lines CRMM1 (de Waard, Kolovou, 
et al., 2015) and CRMM2 (de Waard, Cao, et al., 2015) were compared with model (non-
ocular) cancer cell lines, including A375, derived from a cutaneous melanoma.  The 
mutational or expression status of GNAQ, GNA11, BRAF and BAP-1 (De Waard-Siebinga et 
al., 1995; Luyten et al., 1996; Verbik, Murray, Tran, & Ksander, 1997) in each cell line is 
summarised in Supplementary Table 1. 
To examine human kinome mRNA expression profiles from experimental UM and CoM cell 
models, and to identify new potential networks for clinical intervention, we employed 
NanoString, an unbiased method of mRNA quantification (Kulkarni, 2011).  This allowed for 
the simultaneous measurement of expression dynamics across >500 mRNAs, which 
together constitute the human kinome, a rich source of drug targets (Bago et al., 2016; 
Manning, Whyte, Martinez, Hunter, & Sudarsanam, 2002).  
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Interestingly, whole kinome expression profiles of the ocular melanoma cell lines were 
closely clustered together, despite differential mutational status of GNAQ/11 and BRAF 
genes in UM and CoM cell lines. Notably, this pattern was distinct from the BRAF-mutated 
cutaneous melanoma line A375, and all other cell lines examined (Figure 1B). Amongst the 
ocular melanoma subgroup, discrete kinome clusters were produced that were defined by 
related cell lines. One kinome cluster included the UM lines Mel270 and OMM2.5, which 
were derived from the same patient. A second cluster in cell lines 92.1 and OMM1 contained 
Q209L mutations in the related GNAQ/11 homologues, and a third comprised the related 
CoM lines CRMM1 and 2, which differ in their BRAF mutational status (Figure 1B).  
To deconvolute our whole kinome data, we focused on kinase mRNAs that exhibited 
differential high or low expression levels in melanoma.  We found extremely low levels of 
EGFR mRNA in all UM and CoM cell lines, (Figure 1C): it was minimally ~50 fold lower in 
ocular melanoma cells when compared with carcinoma cell lines and the skin melanoma cell 
line A375.  In marked contrast, CDK2 transcript levels were always in the highest 1-2% of 
kinase mRNAs in all UM (Supplementary Figure 1), and always over-expressed at 2-4 fold 
higher levels in UM and CoM cell lines (Figure 1C). The mRNA encoding a regulator of 
MAPK pathways (TAOK3) was also highly expressed in UM and CRMM1 cells when 
compared to control cells (Supplementary Figure 1).  As internal controls, we confirmed that 
BET-domain containing BRD2 and BRD4 mRNAs were highly expressed in all cells lines 
examined, with no positive selection in melanoma cells (Supplementary Figure 1). As shown 
in Figure 1D, and in full agreement with our expression analysis in cells, EGFR mRNA was 
extremely low, and CDK2 very high, in all 80 human UM examined in the TCGA database. 
Quantitatively across all the samples, mean expression levels of CDK2 transcripts were 
~250-fold higher than those of EGFR (Figure 1D), revealing the enormous range in transcript 
levels detectable by this approach.  
We next established that EGFR protein levels were essentially undetectable in both UM and 
CoM cells, in contrast to all other cancer cells tested, including a cutaneous melanoma. 
Conversely, CDK2 protein levels were markedly higher in the same UM and CoM lysates in 
all the cases examined (Figure 1E), consistent with our transcriptional data. 
Next, we evaluated kinome expression profiles in nine formalin-fixed and paraffin-embedded 
primary UM. Consistently, we observed exceptionally high levels of CDK2 and TAOK3 
mRNAs, in contrast to very low expression of EGFR mRNA, and BRD2 and BRD4 mRNA 
levels were consistently amongst the highest 10% of transcripts examined (Supplementary 
Figures 2A and 2B). Interestingly, there was no correlation between CDK2 (high) or EGFR 
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(low) signatures and chromosome 3 status, a known strong prognostic marker in UM 
(Damato et al., 2011; van Beek et al., 2014), in the samples examined 
Our analysis suggests that kinome-wide mRNA data, and in particular, CDK2 and EGFR 
status, can be used to classify ocular melanoma cell types in vitro and in vivo, and might 
form the basis of a predictive network relevant to understanding differential kinase signalling 
pathways present in UM patients. To examine whether high expression of CDK2 in UM and 
CoM was predictive for sensitivity to chemical CDK2 inhibition, we exposed UM, CoM and 
control cancer cell lines derived from non-ocular sites to the pre-clinical CDK2 inhibitor SNS-
032, the subject of a Phase 1 clinical trial (Tong et al., 2010). By comparing cell viability, we 
observed a broad, non-specific, inhibitory effect (SNS-032 EC50 60-400 nM) in all cells tested 
irrespective of CDK2 mRNA or protein levels (Supplementary Figure 3A). 
Moreover, the clinically approved selective CDK4/6 inhibitor palbociclib (Whittaker, Mallinger, 
Workman, & Clarke, 2017) exhibited a wide range of toxicity across all UM and CoM cell 
lines tested, indicating that its efficacy did not correlate with GNAQ/11 mutational status, or 
uveal compared to conjunctival origin (Supplementary Figure 3B).  
Comparing responses of ocular melanoma cells to kinase and BET-domain inhibitors 
We next assembled a panel of FDA-approved inhibitors, including specific and pan-tyrosine 
kinase inhibitors (TKIs) and the UM candidate selumetinib (Komatsubara, Manson, & 
Carvajal, 2016) and calculated EC50 values associated with cell killing. As expected, UM and 
CoM demonstrated limited sensitivity (EC50 values >1 PM) to a variety of TKIs, including 
those targeting EGFR, whose expression is extremely low in these cells (Figure 1C). 
Interestingly, the MEKi selumetinib exhibited higher cytotoxicity towards UM cells, 
particularly those derived from primary tumours (92.1 and Mel270), with mean EC50 values 
lying in the submicromolar range. Of note, CoM cell lines were also relatively sensitive to the 
non-specific TKI ponatinib, in contrast to all UM cell lines examined. As a positive control 
BCR-ABL-positive K562 CML cells exhibited low nanomolar sensitivity to approved clinical 
TKIs (Figure 2A), whose marked lack of effect in any UM cells was prominent, consistent 
with experimental clinical findings detailing a lack of imatinib response in KIT-positive UM 
(Calipel et al., 2014).   
The resistance of tumour cells to kinase inhibitors can sometimes be overcome by exposing 
them to cellular BET domain inhibitors such as JQ1 (Kurimchak et al., 2016; Stuhlmiller et 
al., 2015). We therefore turned our attention to chemical targeting of Bromodomain (BRD) 
proteins, which are known to regulate expression of oncogenic MYC (Delmore et al., 2011) 
that is frequently upregulated in UM.  Chromosome 8q amplification, which encompasses 
the oncogenic MYC locus, is consistently observed in ~30% of UM patients (Caines et al., 
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2015; Parrella, Caballero, Sidransky, & Merbs, 2001). Patients with UM characterised by 
monosomy 3 and amplified 8q have a statistically-significantly higher risk of developing 
metastatic disease (Damato et al., 2011; van Beek et al., 2014). This risk is enhanced further 
should additional poor prognostic factors be present, such as ciliary body location, epithelioid 
cell type, high mitotic count, and extraocular extension (Damato et al., 2011). A recent study 
concluded that GNAQ/11 mutations conferred single agent sensitivity to JQ1, which potently 
represses MYC transcription in GNAQ/11-mutated UM (Ambrosini et al., 2015). These 
observations suggested that MYC and/or GNAQ/11 mutational status may be important for 
the cellular response to broad transcriptional repressors such as JQ1. The very high levels 
of BRD2 and BRD4 mRNA observed in both UM and CoM cell lines and patient samples 
(Supplementary Figures 1 and 2) prompted us to test the effect of the BET-domain inhibitor 
JQ1 and JQ1(-), an inactive enantiomer, across UM, CoM and non-ocular cell types. As 
shown in Figures 2A and 2B, all UM-derived cells tested were sensitive to JQ1, but not JQ1(-
), exhibiting EC50 values < 500 nM. In addition, we found that the CoM cell lines CRMM1 and 
CRMM2 (WT at GNAQ/11 loci, Supplementary Table 1) were also sensitive to JQ1-induced 
cell death (Figures 2A and 2B). Interestingly, A375 and colorectal HCT116 cells were 
relatively resistant to JQ1, with calculated EC50 values of >10 PM and 2.4 PM respectively, 
suggesting a potential therapeutic window in UM and CoM for small molecules that interfere 
with signalling pathways controlled by BRD4 dependent transcription. 
 
Bioinformatic and pathway analysis of kinase signalling pathways in UM 
Very little is known about dynamic intracellular signalling networks in UM that might 
contribute to the resistance or sensitisation mechanisms to drugs established in other cancer 
cell models (Kurimchak et al., 2016; Stuhlmiller et al., 2015). For example, JQ1 has been 
demonstrated to modulate transcription in proliferative signalling pathways and decrease 
tumour volume in a mouse xenograft GNAQ-mutant model, which coincides with down-
regulation of the anti-apoptotic protein Bcl-XL (Ambrosini et al., 2015). As shown in Figure 
3A, JQ1 exposure caused a highly significant (>2 fold) downregulation of ~ 100 kinase 
mRNAs (representing between 17-24% of the total kinome) in all four UM cell lines 
examined. In contrast, CRMM1/2 cell responses were characterised by up- and down-
regulation of relatively few kinase mRNAs. Interestingly, the whole-kinome response of A375 
cells resembled the UM kinome response following exposure to JQ1, despite the limited 
cytotoxicity demonstrated by JQ1 in this cell line. 
We next evaluated expression dynamics in the context of cancer signalling pathways, which 
has the potential to reveal novel single-agent or combinatorial opportunities for therapeutic 
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intervention, which might avoid unwanted ‘off-target’ effects of very broad transcriptional 
repressors such as JQ1. Ingenuity pathway analysis (IPA) confirmed that JQ1 effects were 
predicted to reduce signalling activity within a variety of proliferative/pro-survival pathways in 
UM, but not CoM, cells (Figure 3B). These include protein kinases that are specifically 
associated with metastatic HGF/c-Met, GDQ, NF-NB and melanocyte-specific signalling 
pathways. In addition, and consistent with the ability of JQ1 to reduce cell viability (Figure 2) 
and promote apoptosis (Ambrosini et al., 2015), we noted a prominent number of kinase 
mRNAs associated with cell death signalling in each of the UM cell lines. In contrast, 
pathway responses were reversed in JQ1-exposed CoM cells CRMM1 and CRMM2 (Figure 
3B), despite an equal cellular sensitivity to JQ1 in vitro (Figure 2A). As noted above, IPA 
analysis of A375 cell response following JQ1 exposure revealed close pathway similarities to 
those induced in UM cells, despite a lack of cellular toxicity to this compound. 
JQ1 reduces the expression of BRD4 and C-MYC in UM cells 
We confirmed JQ1 target-engagement and downstream effects in UM cells, by measuring 
effects on BRD family mRNA (Figure 4A) and evaluating cell cycle distribution 
(Supplementary Figures 4B and 4C).  Together these revealed a JQ1-induced enrichment of 
UM cells in G1 phase of the cell cycle. At 0.5 PM JQ1 (~ EC50 value), there was also a 
significant reduction in the levels of BRD4 mRNA (red) in all UM cell lines examined, 
consistent with repression of BRD family transcription, which occurs through blockade of a 
positive feedback loop (Delmore et al., 2011). Interestingly, CRMM1 and A375 cells 
responded similarly to UM cell lines in terms of BRD4 repression. This was in contrast to 
CRMM2 and HCT116 cells, where low micromolar concentrations of JQ1 either increased 
the levels of BRD2 and BRD4 (CRMM2) or had no significant effect (HCT116). In GNAQ 
mutant UM cells, the transcript levels of BRD2 decreased following JQ1 exposure, whereas 
in GNAQ WT cell lines, JQ1 caused a significant increase in the level of BRD2 mRNA. 
Consistently, c-MYC protein expression was also reduced (Figure 4B) in cell lines exhibiting 
a reduction in BRD4 mRNA (Figure 4A). In agreement with our cell cycle analysis, mRNA 
levels of the MYC transcriptional target CDK4 (Hermeking et al., 2000), which is involved in 
G1 progression, were also reduced following JQ1 exposure (Supplementary Figure 4A). 
Despite BRD4 engagement in both ocular and cutaneous melanoma cell types, no 
correlation between target engagement and subsequent cell death could be established for 
JQ1. This finding is in line with a recent report (Ambrosini et al., 2015), where JQ1-regulated 
c-MYC expression was broadly repressed across all UM samples, whereas apoptosis was 
only observed in a subset of GNAQ mutant cell types.   
JQ1 down-regulates a FOXM1-dependent network of protein kinase mRNAs 
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To evaluate new potentially druggable responsive signalling pathways involved in JQ1-
induced cell death that might be of relevance to inform UM patient therapeutics, we used the 
Reconstruction of Transcriptional Networks (RTN) pipeline to evaluate signalling modules 
(Fletcher et al., 2013).  Kinome-wide mRNA expression data were assembled from 80 UM 
samples in the TCGA database, and compared with kinases identified following JQ1 
treatment of UM cell lines (Figure 3A). This analysis demonstrated a very strong positive 
correlation between mRNA targets of the Forkhead family transcription factor FOXM1 
(Alvarez-Fernandez et al., 2010; Fu et al., 2008) and multiple cell cycle-regulated mitotic 
kinases (Figure 5A). This group included AURKA (Figure 5B), AURKB (Figure 5C), PLK1 
(Figure 5D) and BuBR1/BUB1B (Figure 5E), (but not CDK2, Figure 5F), whose important 
roles as guardians of mitotic entry, progression and exit have established them as potential 
oncology targets. 
Interestingly, the expression of FOXM1-dependent mitotic kinase mRNAs was consistently 
down-regulated following JQ1 exposure in all four UM cell lines and in A375 cells (Figure 
5G, blue shading). In contrast, both up and down-regulation of mitotic kinase mRNAs was 
observed in response to JQ1 in CoM lines CRMM1 and CRMM2 (Figure 5G). Consistently, 
JQ1 exposure led to a potent reduction in the levels of FOXM1 protein expression in the 
three UM cell lines where it could be detected (Figure 5H), similar to effects in BRAF-mutant 
CRMM1, and more apparent than those in BRAF-wt CRMM2 cells (Figure 5H). To gain 
further insight into the JQ1-regulated FOXM1 regulatory network, we performed individual 
FOXM1 and BRD4 siRNA knockdown in Mel270 and A375 cells and analysed effects on 
PLK1 mRNA levels by RT-PCR. As shown in Figure 5I, FOXM1 siRNA decreased FOXM1 
mRNA >3-fold compared to scrambled siRNA controls, and this was accompanied by a >2.3-
fold decrease in PLK1 mRNA levels in Mel270 cells. In the same cell line, knockdown of 
BRD4 was accompanied by a small, but reproducible, decrease in PLK1 mRNA levels. In 
A375 cells, FOXM1 or BRD4 knock-down was also accompanied by a small decrease in 
PLK1 mRNA levels. Importantly, individual knock-down of either BRD4 or FOXM1 in Mel270 
cells led to a marked effect on PLK1 protein levels 48h after transfection, in contrast to A375 
cells, where neither siRNA altered the total levels of PLK1 (Figure 5J). A temporal correlation 
between FOXM1 and PLK1 protein expression was previously reported during cell cycle 
progression in human cells (H. J. Park, Costa, Lau, Tyner, & Raychaudhuri, 2008), and the 
human PLK1 promoter is a known transcriptional target for the cancer-associated FOXM1 
pathway (Chen et al., 2013; Raychaudhuri & Park, 2011). 
Targeting the FOXM1-transcription network with kinase inhibitors 
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Our finding that JQ1 reduced UM cell viability and down-regulated FOXM1-regulated kinases 
suggested a new approach to target proliferative signalling in UM.  We hypothesised that 
chemical repression of the activity of protein kinases in this network might be employed to 
mimic the widespread and potentially non-specific effects observed with JQ1. We therefore 
exposed UM, CoM, A375 and HCT116 cells to chemically distinct inhibitors of PLK1, 
including GSK461364 (Ferrarotto et al., 2016), BI6727/volasertib (Van den Bossche et al., 
2016), the dual PLK1-BRD4 inhibitor BI2536 (Mross et al., 2012) and the investigational 
Aurora B inhibitor (AZD1152, barasertib (Wilkinson et al., 2007)). Cytotoxicity and cell 
viability were determined by combined SRB and MTT assay (Figure 6A and Supplementary 
Figure 5), employing JQ1 and the BRAF V600E inhibitor vemurafenib as experimental 
controls. As shown in Figure 6A, GSK461364, BI2536 and AZD1152 all exhibited non-
selective cytotoxicity, with mean EC50 values <20 nM (Figure 6A). Interestingly, BI6727 
demonstrated clear selectivity in this assay, with low nanomolar cytotoxicity in UM lines, in 
comparison to other cell types examined, including BRAF-mutant A375 (~1 PM) and CRMM1 
CoM (650 nM) cell lines, which both exhibited hypersensitive to vemurafenib. These findings 
were confirmed by clonogenic assays, which showed specific effects of BI6727 on UM cells 
(Figure 6B). Finally, when kinome-wide transcriptional responses to BI6727 in the UM cell 
line 92.1 were compared with the BETi JQ1 (Supplementary Figure 6B), clear mechanistic 
differences between the two compounds became apparent. For example, BI6727 had no 
effect on BRD4 mRNA levels or members of the FOXM1-regulated mRNA network that are 
down-regulated by JQ1. This finding is consistent with recent data suggesting that BI6727 
only binds to the BET domain of BRD4 in cells at concentrations two to three orders higher 
than the EC50 value established here (Gjertsen & Schoffski, 2015). The mechanism of 
BI6727 cytotoxicity in UM cell lines, therefore, appears to be distinct from that of JQ1 and the 
dual-PLK1/BETi BI2536, which we propose might underlie the window of selectivity identified 
in UM cells. 
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DISCUSSION 
In this study, we undertook a transcriptomic and chemical biology approach to evaluate the 
human kinome in two rare melanomas that arise either in the uveal tract (UM) or conjunctival 
membranes (CoM) of the eye. These melanomas receive less attention than metastatic 
cutaneous melanomas, whose mutational status has been exploited clinically with targeted 
BRAF kinase inhibitors. We focused on increasing our understanding of cellular protein 
kinase networks, since they represent important (but currently ineffective) druggable 
modules in metastatic UM downstream of mutated GD-subunits of GNAQ/GNA11. The 
importance of an unbiased understanding of kinome dynamics to guide therapeutic options 
is made clear by a recent dissection of responses to targeted kinase therapies in breast 
cancer models (Bago et al., 2016), and made relevant to UM by the recent discovery of 
pathway-specific kinase inhibitors in human pre-clinical models (Carita et al., 2016).  
A multiplexed approach to simultaneously quantify mRNA expression of the entire human 
kinome in samples from four UM and two CoM cell lines facilitated the identification of a 
kinome mRNA signature that was specific to UM and CoM. Several kinase mRNAs are 
highlighted by our analysis: EGFR, (low expression) and CDK2 and TAOK3 (high 
expression). In agreement with these findings, EGFR levels have previously been reported 
to be low or undetectable in immortalized UM cell lines (Amaro et al., 2013). In contrast, 
Amaro and colleagues reported high levels of EGFR in the cell lines ‘Mel285’ and ‘Mel290’. 
However, these cells are highly unusual, and do not display the typical antigens associated 
with melanoma (e.g. MelanA) (Amaro et al., 2013; Griewank et al., 2012; van Dinten et al., 
2005). The clinical or signalling relevance of high basal mRNA levels of CDK2 and TAOK3, 
the latter potentially lying downstream of GNAQ/11 as a transducer of MAPK pathway 
signalling in UM, remains unknown, although clear co-segregation of these mRNAs as part 
of a unique UM signature (Figure 1) might be useful for future diagnostic applications.  
CDK2 protein kinase activity is modulated by cancer-associated Cyclin E and p27Kip 
regulatory partners, and is classically associated with G1/S phase progression. In 
melanocytes, CDK2 levels are under the control of melanogenesis-controlled transcription 
factor (MITF) (Du et al., 2004), and we speculate that MITF is also responsible for the high 
levels of CDK2 observed in ocular melanomas (Figure 1) as previously established in distinct 
UM models (Yan et al., 2012).  Consistent with a general proliferative role for CDK2, all UM 
and CoM cells studied exhibited sensitivity to the CDK2 inhibitor SNS032, although effects 
were not nearly as marked as those measured with Aurora B or PLK1 inhibitors. During the 
course of our studies, we confirmed that selumetinib (a MEKi currently undergoing phase III 
clinical trials in in patients with metastatic UM) was modestly potent at killing cultured UM 
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cells, including two cell lines derived from metastatic sites (Figure 2A). However, no clear 
beneficial patient outcome has been observed following a phase II clinical trial of the TKi 
sunitinib (SUAVE) (Blum et al., 2016; Sacco et al., 2013) or evaluation of selumetinib 
alongside the alkylating agent temozolomide, where 97% of patients treated with selumetinib 
suffered adverse effects, with 37% requiring reductions in dosage, with little improvement in 
progression free survival and none in overall survival reported (Carvajal et al., 2014).  
Although JQ1 has not yet been tested as a targeted clinical agent in UM, this BETi exhibits 
very broad anti-cancer effects, and has previously demonstrated inhibition of tumour growth 
in an animal model (Ambrosini et al., 2015), consistent with high levels of transcriptional 
repression revealed in our UM study (Figures 3 and 5). We extend these published findings 
by demonstrating that CoM cell models also exhibit sub-micromolar sensitivity to JQ1, 
despite GNAQ/11-wt status and the presence of a BRAF mutation in CRMM1, which 
sensitises these cells to the V600E-selective BRAF inhibitors PLX4720 (Riechardt et al., 
2015) and vemurafenib (PLX4032) (Figure 6A). When enrichment for mRNAs in specific 
canonical pathways and their associated cellular functions were analysed, the likely 
functional consequences on cell survival and proliferative mechanisms through kinome 
reprogramming by JQ1 in UM and CoM cells became apparent (Figure 3B). Interestingly, 
although each of these ocular melanoma models were sensitive to similar concentrations of 
JQ1 in vitro (Figure 2), the ‘downstream’ transcriptional effects on cell cycle, proliferation and 
apoptotic kinase networks were essentially reversed in CoM cells. These findings suggest 
that the specific mechanism of cell killing by JQ1 may vary between melanomas of different 
cellular origin, rather than simply as a function of GNAQ/11 status (Ambrosini et al., 2015).  
A JQ1-responsive transcriptional network that influences UM cell survival 
The presence of a JQ1-regulated FOXM1 transcriptional network in model UM cells was 
further evaluated to reveal a similar strong correlation in UM patient samples between 
absolute levels of FOXM1 mRNA, and that of the same family of proliferative protein 
kinases. CDK1, PLK1, Aurora A and Aurora B are individually rate-limiting for mitotic entry, 
satisfaction of components of the spindle assembly checkpoint and mitotic exit (Nigg, 2001; 
Otto & Sicinski, 2017). In agreement with our analysis (Figure 5), BRD4 siRNA phenocopies 
JQ1 exposure in UM (Ambrosini et al., 2015) and BRD4 siRNA potently suppresses Aurora 
B mRNA and protein (You et al., 2009). JQ1 has recently been shown to control a 
transcriptional FOXM1 network in ovarian cancer cells (Z. Zhang et al., 2016), and also 
controls expression of cell cycle genes such as murine PLK1 (Matzuk et al., 2012) in vivo. 
Kinome-wide signatures obtained with clinical and publicly-available (TCGA) UM patient 
samples demonstrated that the FOXM1-regulated network contains a number of druggable 
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protein kinases, including Aurora A, Aurora B and PLK1, all of which have previously been 
targeted with small molecules in haematological and solid tumours. Based on our analysis of 
this UM-responsive kinome network, and a direct association with JQ1-induced cell death in 
UM and CoM cell lines (including the pre-metastatic UM cell line Mel270 and corresponding 
metastatic cell line derived from the same patient, OMM2.5), we hypothesised that chemical 
inhibition of the catalytic activity of these mitotic kinases might also kill UM cells. Strikingly, 
we found that the specific Aurora B inhibitor AZD1152 (barasertib), which exhibits antitumour 
efficacy in clinical indications (Girdler et al., 2006) and the PLK1 inhibitor GSK461364, both 
possess cell killing activity at nanomolar concentrations in all cell types tested. In contrast, 
the phase III PLK1 inhibitor BI6727 (volasertib), which received FDA breakthrough therapy 
designation in 2013 (Van den Bossche et al., 2016), was as effective at killing UM cells in 
vitro as GSK461364 and AZD1152, and also demonstrated a window of selectivity over 
other cell types when analysed using complementary experimental approaches (Figure 6).  
Relevance of kinome profiling to future clinical strategies in UM  
Our analysis raises the possibility that comparative kinome profiling of patient-derived 
samples could also be employed as a prognostic or predictive tool to help patient profiling in 
pigmented tumour types, including many UM and CoM. In order to help progress the 
treatment of metastatic UM, the potential exists for transcriptional profiling to be rapidly taken 
up as part of experimental and clinical protocols (Barlesi et al., 2016; Mashima et al., 2015; 
S. M. Park et al., 2016). For example, comparative dynamic kinome profiling between 
primary and metastatic biopsies from the same patient might reveal cellular dynamics of 
signalling, and how this becomes subverted by GNAQ/11 mutations or kinome ‘rewiring’ 
during metastatic progression. Such knowledge might enhance the evidence-based testing 
of drugs as clinical monotherapies or as combinations, whilst permitting direct assessment of 
drug target engagement, efficacy and kinome-wide responses in patients.  Our study 
demonstrates a transcriptional kinase network controlled by master transcription factors 
BRD4, MYC and FOXM1, which might be more specifically targeted with antimitotic agents 
in metastatic UM, where patients remain in urgent need of targeted therapeutic options. Our 
discovery of a high level of vulnerability of UM cells to the specific PLK1 inhibitor BI6727 
(volasertib), suggest new approaches employing anti-mitotic kinase inhibitors to help combat 
and reduce the metastatic burden in this devastating disease. 
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MATERIALS AND METHODS 
Human subjects and metastatic tumour cell analysis 
All primary UM samples were provided by the Ocular Oncology Biobank (Research Ethics 
Committee Reference 16/NW/0380) as part of a Health Research Authority approved study: 
Research Ethics Committee Reference 11/NW/0759. The study was conducted in 
accordance with the Declaration of Helsinki and informed consent was obtained from all 
human subjects. Total RNA was isolated from approximately 2 x 8 Pm sections of tumour cut 
from formalin fixed paraffin embedded enucleated eyes, using standard techniques with an 
RNeasy kit (Qiagen), and NanoString analysis of the human kinome and appropriate control 
housekeeping genes was performed in duplicate. 
Cell lines, genotypic and small molecules 
Human cell lines derived from human UM (92.1, Mel270, OMM2.5 and OMM1), colorectal 
carcinoma (HCT116), cervical carcinoma (HeLa), breast cancer (ZR-75-1) and CML (K562) 
were cultured in RPMI media supplemented with 10% FBS, 100U/ml penicillin and 100 
mg/ml streptomycin. The Conjunctival Melanoma (CoM) cell lines CRMM1 and CRMM2 
were cultured in F12K media supplemented with 10% FBS containing 100 units/ml penicillin 
and 100 mg/ml streptomycin. All cells were maintained in a humidified 5% CO2 atmosphere 
and genotyped in-house. All UM and CoM cell lines were a kind gift from Professor Martine 
Jager, Dept Ophthalmology, Leiden University Medical Centre, Leiden, The Netherlands. 
Cell line BRAF mutation status was determined using Qiagen Therascreen BRAF RGQ PCR 
Kit. GNAQ/GNA11 mutation status was determined by Sanger sequencing. Chromosome 3 
and Chromosome 8 status was determined by Multiplex Ligation Dependent Probe 
Amplification and/or SNP6.0 analysis. 
All protein kinase inhibitors were purchased from Selleck Chemicals (Houston, TX, USA), 
with the exception of imatinib, which was purchased from SignalChem. JQ1 and JQ1- were 
generous gifts from the SGC-Oxford. All compounds were dissolved in DMSO at 10 mM, and 
serially diluted in DMSO, unless indicated otherwise. 
Cell proliferation, clonogenic assay and cell viability assays 
Cells were seeded in a 96-well plate at a density of 4,500 cells/well and left to adhere for 24 
hours. Cells were exposed in triplicate to the indicated compound concentration, dissolved in 
a final concentration of 0.1% (v/v) DMSO. Cell viability and cytotoxicity was determined after 
5 days by MTT assay or SRB assay, or after 7 days after fixation and staining in a 1% (w/v) 
methylene blue, 80% (v/v) methanol solution. Thiazolyl Blue Tetrazolium Bromide (Sigma-
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Aldrich, St-Louis, Mo, USA) was dissolved in PBS at a concentration of 5 mg/ml and 5 Pl in 
100 Pl media added to the cells for 3 hours. Reactions were stopped by addition of 50 Pl 
acidified 10% SDS. Absorbance was measured at 570 nm. Cell viability was determined as 
the percentage of growth compared to control cells (incubated in 0.1% (v/v) DMSO alone), 
and EC50 values were calculated using GraphPad Prism 6 software using data from three, or 
occasionally two, independent experiments, each performed in triplicate. Values are mean ± 
SD. 
NanoString nCounter analysis and RT-PCR 
Samples were prepared essentially as described previously (Bago et al., 2016). Briefly, the 
appropriate cells were collected, counted, washed in PBS and snap‐frozen until required. 
Pellets were thawed and resuspended at a concentration of ~6,500 cells/μl in RLT buffer 
(Qiagen). The equivalent of ~10,000 cells (~1.5 μl) was employed for direct kinase mRNA 
quantification, without the need for further mRNA purification or amplification. mRNAs were 
hybridised to NanoString human kinome barcode probes and control code sets, and kinase 
mRNA levels quantified using the nCounter colour barcoding system after count 
normalisation with internal housekeeping genes and 8 negative controls. For total copy 
numbers, replicate normalised count values were averaged. P‐values were calculated using 
a paired t‐test (GraphPad Prism software) by comparing treated and control count data for 
each mRNA. The complete UM kinome datasets are available as Supplementary datasets 
online. Complete cDNA was generated from total RNA using GoScript Reverse Transcription 
system (Promega), using 1 Pg RNA per reaction and 0.5 Pg of Random primer. qPCR was 
performed using a Comparative Ct (''Ct) method on an Applied Biosystems (AB) 
StepOnePlus machine, a Power SYBR Green PCR Master Mix and the following primer 
pairs. PLK1: 5’-AAGAGGAGGAAAGCCCTGAC-3’ and 5’-TTCTTCCTCTCCCCGTCATA-3’, 
FOXM1: 5’-TGCAGCTAGGGATGTGAATCTTC-3’ and 5’- GGAGCCCAGTCCATCAGAACT-
3’, BRD4: 5’-CCATGGACATGAGCACAATC-3’ and 5’TGGAGAACATCAATCGGACA-3’, 
GAPDH: 5’-TTCACCACCATGGAGAAGGC-3’ and 5’-CCCTTTTGGCTCCACCCT-3’. 
Expression levels were normalized to GAPDH mRNA using AB software.  
Cell lysate preparation and Immunoblotting 
Cells were collected, washed 3 x in PBS and then lysed in RIPA buffer (1% (v/v) SDS, 1% 
Tergitol type NP-40, 50 mM Tris (pH 7.4), 150 mM NaCl, 1 x protease inhibitor cocktail tablet 
(Roche). Cell lysates were sonicated on ice and insoluble matter cleared by centrifugation.  
Protein concentration was determined using a Pierce BCA Protein Assay Kit and 30 Pg of 
each sample were denatured in 1X Laemmli sample buffer, heated at 95°C for 5 min and 
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then analysed by SDS-PAGE using 10% (v/v) polyacrylamide gels.  Standard Western 
blotting procedures were followed. Membranes were incubated with the following primary 
antibodies MYC (D84C12), cyclin-D1 (#2922), FOXM1 (D12D5), PLK1 (Cell Signaling 
Technologies) and alpha tubulin (TAT-1, CRUK) overnight. Antibodies were detected with 
appropriate HRP-conjugated secondary antibodies using ECL. 
 
Computational and Pathway analyses 
Computational analysis including PCA and data visualisation was performed using the R 
software package for statistical computing (https://www.r-project.org/) and commercial 
Ingenuity Pathway Analysis software (QiagenBiosciences).  
The RTN pipeline was carried out in R using the RTN package with default parameters. This 
pipeline is able to reconstruct genome-wide transcriptional networks from microarray or 
RNA-seq data using an information-based theoretical approach, which it uses to search for 
network hubs whose first neighbours are enriched with genes provided from a signature 
provided by the user. Normalised and batch-corrected gene expression data for Uveal 
Melanoma patients was downloaded from the MD Anderson TCGA MBatch website 
(http://bioinformatics.mdanderson.org/tcgambatch/) and used for the network reconstruction 
phase. The list of potential network hubs was limited to transcription factors found within the 
AnimalTFDB 2.0 database (H. M. Zhang et al., 2015). The network shown in Figure 5A 
represents a consensus of the analyses using gene signatures from the four UM cell lines. 
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FIGURE LEGENDS 
Figure 1. Whole kinome profiling of a panel of human cancer cells 
Principal component analysis (PCA) of whole kinome mRNA expression from (A) RNA-Seq 
patient data from the TCGA, where cancer subtypes are shaded and grouped, and relative 
data density distribution is plotted on the horizontal and vertical axes and (B) the quantified 
kinome mRNA from model cell lines measured using NanoString. Note the distinct 
separation between ocular melanomas and a panel of epithelial and mesenchymal –derived 
non-ocular cell lines, including the experimental cutaneous melanoma line A375. (C) EGFR 
and CDK2 mRNA levels were quantified in a panel of cell lines by NanoString. Mean counts 
for each protein across the UM and CoM, and non-ocular cells have been annotated on the 
figure. D) Jittered scatter-plot showing relative expression levels of EGFR and CDK2 in 
human UM patient samples from the TCGA database. The mean expression value (Log2 
scale) is indicated by the horizontal line. E) Analysis of EGFR and CDK2 protein expression 
levels in RIPA cell lysates.  Dashed boxes highlight the ocular melanoma samples. Alpha 
tubulin was used to confirm similar protein loading. 
Figure 2.  Assessing the sensitivities of UM to a panel of experimental and FDA-
approved kinase and BET-domain inhibitors 
(A) Mean EC50 values were obtained using MTT cell viability assays (mean ± S.D. from 
triplicate assays, N=2). The indicated cell lines were incubated with increasing 
concentrations of the appropriate compound in a range between 10 nM and 10 PM, and 
compared to 0.1% (v/v) DMSO controls. For ease of analysis, green boxes highlight EC50 
values <1 PM, grey boxes EC50 values between 1 PM and 10 PM, and white boxes EC50 
values >10 PM. ND=not determined (B) 4,500 cells were exposed to increasing 
concentrations of JQ1 and cell viability was determined using MTT and SRB assays. 
 
Figure 3. Quantification of JQ1-induced changes in human kinome mRNA levels in UM 
and CoM cell lines 
(A) Kinome mRNAs were quantified using NanoString technology, following JQ1 exposure 
and compared to DMSO-treated controls. The number of kinases whose expression 
changed by more than 2 fold were counted and converted to a percentage of the 522 
kinases analysed. Kinases were discarded from the analysis if JQ1(-) caused a similar 
response (although this was only documented in two cases). Kinases with increased or 
decreased expression relative to untreated controls are shown on the positive or negative 
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axis respectively. (B) Ingenuity pathway analysis of the UM and CoM cell lines exposed to 
JQ1 for 24 hours. Red or blue shaded cells indicate pathways or functional terms that were 
predicted to be activated or repressed respectively, according to the expression changes 
observed following JQ1 exposure. Ingenuity pathway analysis provides both a p-value for 
enrichment of a category as well as a measure of how consistent the fold changes are with 
increased/decreased activity of that category (z-score). The least significant enrichment 
amongst the categories shown had a p value of < 0.0001.   
Figure 4. Confirmation of cellular JQ1 target engagement by transcriptomics 
(A) Quantified mRNA counts (mean ± S.D.) of BRD family members after incubation with 
DMSO (blue bars) or 500 nM JQ1 (red bars) or 2 PM JQ1 (green bars). Statistical 
significance between JQ1-treated cells and the controls was assessed using paired t-tests. 
*=p<0.05, **=p<0.01, ***=p<0.001. (B) Endogenous MYC protein was detected by western 
blot of lysates exposed to DMSO (control) or the indicated concentrations of JQ1.  
Figure 5. Reconstruction of Transcriptional Networks (RTN) analysis: JQ1 mediates 
expression of a FOXM1-regulated cell cycle kinase network that includes PLK1 
(A) Schematic of RTN findings. FOXM1 was predicted to be a key transcription factor that 
controls a JQ1-dependent transcriptomic kinome signature (adjusted p-value for overlap: 
2.0e-6). A consensus of the putative FOXM1-dependent kinases identified in the analysis 
are shown in the network. (B-F) Statistical correlation analysis between FOXM1 and (B) 
AURKA, (C) AURKB, (D) PLK1, (E) BUB1B/BubR1 and (F) CDK2, in the clinical TCGA UM 
patient cohort (N = 80). (G) Temporal profiling of the putative FOXM1 targets identified by 
RTN analysis (sample replicates shown). Blue boxes represent a reduction in gene 
expression, red have increased gene expression. (H) Endogenous FOXM1 protein 
expression levels were analysed after exposure to the indicated compound (I) PLK1 mRNA 
levels were quantified by RT-PCR after FOXM1 (blue) or BRD4 (red) siRNA knock-down (48 
h) in either Mel270 or A375 cells. (J) PLK1 protein expression levels were analysed by 
western blotting 48h after control, BRD4 or FOXM1 siRNA transfection protocols in Mel270 
or A375 cells. Similar results were seen in an additional experiment. 
Figure 6. UM cell lines are highly sensitive to the PLK1 inhibitor BI6727  
(A) Cells were exposed to increasing concentrations of the stated compounds. Mean EC50 
values (nM) were obtained from two independent cell viability assays, SRB and MTT, each 
performed in triplicate. (B) Colonies formed from single cells were stained with methylene 
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blue following 7 days exposure to increasing concentrations of BI6727 ranging between 1 
nM and 30 nM. DMSO was employed as a mock compound control.  
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Supplementary Table 1 
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Supplementary Table 1 
 
 
 
 
 
 
 
 
 
 
*Cell lines derived from the same patient; + = present by immunohistochemistry; ND = not determined; NMD = No 
mutation detected; L = loss; G = Gain; N = Normal; N# = copy neutral with LOH 
¥ = EIF1AX data taken from Amirouchene-Angelozzi et al, Mol Oncol. 2014 8:1508-20 
 
 
  
 
Characteristics 
Cell Line 
92.1 OMM.1 Mel270* Omm2.5* CRMM1 CRMM2 A375 
       Origin 
 
Primary 
UM 
Subcutane
ous 
UM  
Primary 
UM 
Liver UM 
metastasis 
Primary 
CoM 
Primary 
CoM 
Malignant 
cutaneous 
Melanoma 
Nuclear BAP1  + + + + ND ND ND 
Chromosome 3 3pL ND N# N ND ND ND 
Chromosome 8 G ND N# N ND ND ND 
GNAQ mutation c.626 A>T NMD c.626 A>C c.626 A>C ND ND ND 
GNA11 mutation NMD c.626 A>T NMD NMD ND ND ND 
SF3B1 mutation NMD NMD NMD NMD ND ND ND 
EIF1AX 
mutation 
c.17 G/A¥ NMD ND NMD ND ND ND 
BRAF mutation NMD NMD NMD NMD V600E NMD V600E 
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SUPPLEMENTARY FIGURE LEGENDS 
Supplementary Table 1. Genetic analysis of cell lines evaluated in this study. 
Chromosome and mutational status of common melanoma-associated genes in 
experimental cell lines. 
Supplementary Figure 1. Rank order of kinase mRNAs in UM, CoM and control human 
cancer cell lines. 
In terms of normalised counts, the most highly expressed human kinase mRNAs in the 
indicated cell line are quantified, beginning with the highest, with BET-domain proteins BRD2 
and BRD4 included for comparison. The rank mRNA levels of BRD2 (green), BRD4 (red), 
CDK2 and TAOK3 (pink) mRNAs are indicated. 
Supplementary Figure 2. Rank order of kinase mRNAs from archival UM samples. 
(A) Kinome mRNA levels from three individual UM patient samples were quantified by 
NanoString and the highest 10% are shown in the figure, starting with the highest. BRD2 
(green), BRD4 (red), CDK2 and TAOK3 (pink) mRNAs are indicated. (B) The mRNA levels 
of CDK2, TAOK3, EGFR, BRD2 and BRD4 from each the three specific samples in (A), and 
an additional 6 patient samples, were quantified. Chromosome 3 status (monosomy (M3) or 
disomy (D3)) for each sample was determined by is shown. 
Supplementary Figure 3. High levels of CDK2 protein and mRNA are not predictive for 
inhibitor sensitivity 
 MTT assays were performed after 4500 cells were incubated in triplicate (N=2) with 
increasing concentrations of (A) SNS032 or (B) palbociclib in mid-log ranges between 1 nM 
and 10 PM for 5 days, and compared to 0.1% (v/v) DMSO controls.  
Supplementary Figure 4. JQ1 represses CDK4 mRNA and induces a G1 cell cycle 
arrest in UM cells. 
(A) Normalised transcript levels of CDK4 mRNA measured after exposure to DMSO, JQ1 or 
JQ1(-) with standard deviation error bars. Statistical significance between JQ1 treated cells 
and controls was demonstrated using paired t-tests. *=p<0.05, **=p<0.01, ***=p<0.001. (B) 
92.1 and OMM1 UM cells were exposed to 1 mM JQ1 for 48 hours then stained with 
propidium iodide (PI).  DNA content was measured by flow cytometry and the percentage of 
cells in each phase of the cell cycle was estimated. (C) 92.1 and OMM1 lysates were 
resolved by SDS-PAGE and protein levels of Cyclin D1 determined by western blotting. a-
tubulin was used to control for protein loading.  
Supplementary Figure 5. Comparative analysis of targeted compounds in cell models.  
The indicated cell lines were incubated with increasing concentrations of compounds 
between the mid-log ranges of 0.03 nM to 1 PM (GSK461364, AZD1152, BI2536 and 
BI6727) or 1 nM  to 10 PM (vemurafenib and JQ1) and compared to 0.1% (v/v) DMSO 
controls. Cytotoxicity was determined by SRB assay.  
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Supplementary Figure 6. Distinct transcriptional effects of JQ1 and BI6727 in 92.1 
cells  
Quantified mRNA counts (mean ± S.D.) of BRD family members after incubation with either 
(A) JQ1 or (B) BI6727. (C) Mitotic kinases (including the PLK family, which are targets of 
BI6727) were quantified after exposure to JQ1 or (D) BI6727.  Statistical significance 
between compound-treated cells and the controls was assessed using paired t-tests. 
*=p<0.05, **=p<0.01, ***=p<0.001. (E) mRNAs were quantified using NanoString technology, 
following JQ1 or BI6727 exposure and compared to DMSO-treated controls. The number of 
kinases whose expression changed by more than 2 fold were counted and converted to a 
percentage of the 522 kinases analysed. Kinases with increased or decreased expression 
relative to untreated controls are shown on the positive or negative axis respectively. 
 
